scorecardresearch
Business Today
Subscribe
Immersives UPSTART G20 Summit Corporate Petrol-Diesel Weather BT Bazaar
BT 100 BT Accenture PwC De-risking the Future BT-TR GCC Listing
Clear all
Search

COMPANIES

No Data Found

NEWS

No Data Found
Sign in Subscribe
events
Special
News
Markets
Stocks
Bafna Pharmaceuticals Ltd

Feedback
Bafna Pharmaceuticals Ltd

Bafna Pharmaceuticals Ltd (BAFNAPH) Share Price

  • Sector: Pharmaceuticals (Small Cap)
  • Volume: 4,031
Sep 11, 2023 15:42 IST-
  • NSE
  • BSE
  • Share
    • Whatsapp
    • Twitter
    • Facebook
₹92.55
₹0.00 (0.00%)
₹92.55 Low
Today’s Performance
₹92.55 High
₹77.05 Low
52 Week’s Performance
₹124.45 High

STOCK ANALYSIS

STOCK PERFORMANCE

  • 1 Day 0.00%
  • 1 Week -4.98%
  • 1 Month -0.96%
  • 3 Months -21.73%
  • 6 Months -0.48%
  • 1 Year -15.48%
  • 3 Years 57.92%
  • 5 Years 37.33%

PEER COMPARISON

STOCK SUMMARY

  • Face Value (₹) 10.00
  • Beta 0.07
  • 52-Week Low (₹) 77.05
  • 52-Week High (₹) 124.45
  • Price-to-Book (X)* 3.04
  • Dividend Yield (%) 0.00
  • Price-to-Earnings (P/E) (X)* 13.69
  • Earnings Per Share (₹) 6.90
  • Sector Price Earning (X)* 33.20
  • Market Cap (₹ Cr.)* 218.94
  • * Vaues as of last close price

COMPETITORS

BT TV

thumb 39:53 Historic India-Middle East-Europe Corridor Puts China On Notice
THUMB 5:05 Delhi Tops In Terms Of Electric Buses After Arvind Kejriwal Govt Introduces 400 New Buses
thumb 4:42 The India-Middle East-Europe Corridor: A Counter To China's Belt & Road Initiative
THUMB 4:04 Putin Praises Modi’s ‘Make In India’, Cites Example To Russian Auto Industry
THUMB 9:44 Tata Motors' Electrifying Future: In Conversation With Shailesh Chandra On EV Expansion
View more

FINANCIAL ANALYSIS

Income Statement (₹ Cr.)
Balance Sheet (₹ Cr.)
Cash Flow (₹ Cr.)
Income Statement (₹ Cr.)
Balance Sheet (₹ Cr.)
Cash Flow (₹ Cr.)

RATIO ANALYSIS

Return on Equity (%)
Return on Assets (%)
Price-to-Earnings (P/E) (X)
Price to Book (x)
Return on Capital Employed (%)
Enterprise Value to EBITDA (X)
Net Profit Margin (%)
Gross Profit Margin (%)
EBITDA Margin (%)
Return on Equity (%)
Return on Assets (%)
Price-to-Earnings (P/E) (X)
Price to Book (x)
Return on Capital Employed (%)
Enterprise Value to EBITDA (X)
Net Profit Margin (%)
Gross Profit Margin (%)
EBITDA Margin (%)

SHAREHOLDING PATTERN

Summary (as on 30 sep 2022)

DEALS

No Data For Block Deal.

*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
Aug 18, 2015 Sell
Bafna Pharmaceuticals L ,AMRI BAI BAFNA
  • Qty 158400
  • Average Price ₹30.92
Apr 10, 2014 Sell
Bafna Pharmaceuticals L ,S A MANIKANDAN
  • Qty 111000
  • Average Price ₹27.86
Apr 10, 2014 PURCHASE
Bafna Pharmaceuticals L ,PILOT CONSULTANTS PVT LTD
  • Qty 208756
  • Average Price ₹27.63
Jul 21, 2014 Sell
Bafna Pharmaceuticals L ,GAJANAN ENTERPRISES
  • Qty 88541
  • Average Price ₹36.97
Jul 21, 2014 PURCHASE
Bafna Pharmaceuticals L ,GAJANAN ENTERPRISES
  • Qty 94380
  • Average Price ₹37.85
Jan 05, 2015 PURCHASE
Bafna Pharmaceuticals L ,SUBRAMANIAN SHANMUHAM
  • Qty 100000
  • Average Price ₹33.50
Nov 26, 2013 PURCHASE
Bafna Pharmaceuticals L ,YADAV PALAT
  • Qty 212023
  • Average Price ₹31.74
Nov 26, 2013 Sell
Bafna Pharmaceuticals L ,MANAV N PATEL
  • Qty 496060
  • Average Price ₹32.91
Nov 26, 2013 Sell
Bafna Pharmaceuticals ,YADAV PALAT
  • Qty 212023
  • Average Price ₹33.24
Nov 26, 2013 Sell
Bafna Pharmaceuticals ,MANAV N PATEL
  • Qty 496060
  • Average Price ₹32.91
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.

FAQ’S

What was Bafna Pharmaceuticals Ltd share price previously?
Bafna Pharmaceuticals Ltd share price was down by 0.00% from the previous closing price of ₹92.55.
Who are peers of Bafna Pharmaceuticals Ltd?
The peers of Bafna Pharmaceuticals Ltd are Alkem Laboratories Ltd, Cipla Ltd, Glenmark Pharmaceuticals Ltd, Divis Laboratories Ltd, Sun Pharmaceuticals Industries Ltd, Syngene International Ltd, Aurobindo Pharma Ltd, Lupin Ltd, Biocon Ltd, Dr Reddys Laboratories Ltd, Torrent Pharmaceuticals Ltd, Gland Pharma Ltd, Glaxosmithkline Pharmaceuticals Ltd, Zydus Lifesciences Ltd,
Who is/are the promoter/promoters of Bafna Pharmaceuticals Ltd?
The promotor/promotors of Bafna Pharmaceuticals Ltd are Babulal Kamlesh Kumar, Shanmugam Hemalatha, Akilapriya Chandrashekar Raju, Palamadai Krishnan Sundaresan, Ravichandran Chitra, Atul Sachdeva, Vishnu Vasudeva Kuppa, Upendar Mekala Reddy, Krishna Yeachuri, Vinayak Dinesh Dendukuri, Upendar Mekala Reddy, Krishna Yeachuri.
What has been 52-week high of Bafna Pharmaceuticals Ltd stocks?
The highest price of Bafna Pharmaceuticals Ltd stock is ₹124.45 in the last 52-week.
What is the share price of Bafna Pharmaceuticals Ltd (BAFNAPH) today on NSE?
As on Sep 11, 2023, Bafna Pharmaceuticals Ltd (BAFNAPH)’s share price on NSE is Rs 92.55
What is the market cap of Bafna Pharmaceuticals Ltd (BAFNAPH?)
The current market capitalisation of Bafna Pharmaceuticals Ltd (BAFNAPH) is 218.94 crores
What is Bafna Pharmaceuticals Ltd Share symbol?
The symbol of Bafna Pharmaceuticals Ltd is BAFNAPH.
What is the PE ratio of Bafna Pharmaceuticals Ltd (BAFNAPH)?
The current PE ratio of Bafna Pharmaceuticals Ltd (BAFNAPH) is 13.69.
What is the PB ratio of Bafna Pharmaceuticals Ltd (BAFNAPH)?
The current PB ratio of Bafna Pharmaceuticals Ltd (BAFNAPH) is 3.04.
Today’s High & Low share prices of Bafna Pharmaceuticals Ltd (BAFNAPH) on NSE?
Today, the share price of Bafna Pharmaceuticals Ltd (BAFNAPH) on NSE touched a high of Rs 92.55 and a low of Rs 92.55
What price did Bafna Pharmaceuticals Ltd (BAFNAPH) shares open on the NSE today?
On NSE, the share price of Bafna Pharmaceuticals Ltd (BAFNAPH) opened at Rs 92.55
What is the 52-week high of Bafna Pharmaceuticals Ltd (BAFNAPH)?
The 52-week high price of Bafna Pharmaceuticals Ltd (BAFNAPH) is Rs 124.45
What is the 52-week low of Bafna Pharmaceuticals Ltd (BAFNAPH) ?
The 52-week low price of Bafna Pharmaceuticals Ltd (BAFNAPH) is Rs 77.05

ABOUT BAFNA PHARMA.

Bafna Pharmaceuticals Ltd, incorporated in the year 1995, has its registered office in Bafna Towers New No 68, Old No 299 Thambu Chetty St, Chennai, Tamil Nadu, 600001, 91-44-25267517/25270992/4267755, 91-44-25231264/42677599. The main industry in which Bafna Pharmaceuticals Ltd operates is Pharmaceuticals - Indian - Formulations.

Auditor/Auditors for Bafna Pharmaceuticals Ltd is/are R Sathyanarayanan & Co/Brahmayya & Co. In the main management, Shanmugam Hemalatha is chairman and Vishnu Vasudeva Kuppa is the company secretary for Bafna Pharmaceuticals Ltd.

  • BKK Babulal Kamlesh Kumar Non-Exec. & Independent Dir.
  • SH Shanmugam Hemalatha Chairperson / Executive Direct
  • ACR Akilapriya Chandrashekar Raju Non-Exec & Non-Independent Dir
  • PKS Palamadai Krishnan Sundaresan Non-Exec. & Independent Dir.
  • RC Ravichandran Chitra Non-Exec. & Independent Dir.
  • AS Atul Sachdeva Non-Exec & Non-Independent Dir
  • VVK Vishnu Vasudeva Kuppa Company Sec. & Compli. Officer
  • UMR Upendar Mekala Reddy Additional Non Independent Non
  • KY Krishna Yeachuri Addtnl Non-Exe Dir &Indpnt Dir
  • VDD Vinayak Dinesh Dendukuri Whole Time Director (Operatio
  • UMR Upendar Mekala Reddy Additional Director
  • KY Krishna Yeachuri Additional Director

Top Stories

Thank you! Your transaction has been completed successfully.
Sorry! Transaction failed. Please try again later.

DATA SOURCES: Corporate data, historical price & volume data published on this website have been sourced from CMOTS Internet Technologies Pvt. Ltd. BSE Quotes and NSE Quotes have been sourced from BSE Limited and NSE Data & Analytics Limited, respectively. All timestamps reflected here are in IST (Indian Standard Time). Stock Analysis section has been sourced from the mentioned partners.

DISCLAIMER: Any and all content on this website, including the tools/ analysis, is provided to you only for convenience and on an “as-is, as-available” basis without representation and warranties of any kind. The content and any output of such tools/ analysis is for informational purposes only and should not be relied upon or construed as investment advice or guarantee for any specific performance/ returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this website, you agree to the Terms of Service and Privacy Policy.